BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Conforti C, Dianzani C, Zalaudek I, Cicala M, Persichetti P, Giuffrida R, Morariu S, Neagu N. Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review. Journal of Dermatological Treatment. [DOI: 10.1080/09546634.2020.1836313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Hong JJ, Hadeler EK, Mosca ML, Brownstone ND, Bhutani T, Liao WJ. TNF-Alpha Inhibitors and Ustekinumab for the Treatment of Psoriasis: Therapeutic Utility in the Era of IL-17 and IL-23 Inhibitors. Journal of Psoriasis and Psoriatic Arthritis 2022;7:79-92. [DOI: 10.1177/24755303211047479] [Reference Citation Analysis]
2 Rakowsky S, Papamichael K, Cheifetz AS. Choosing the right biologic for complications of inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2036122] [Reference Citation Analysis]
3 Reiff DD, Stoll ML, Cron RQ. Precision medicine in juvenile idiopathic arthritis—has the time arrived? The Lancet Rheumatology 2021;3:e808-17. [DOI: 10.1016/s2665-9913(21)00252-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wu J, Smogorzewski J. Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases. Dermatol Ther 2021;34:e14883. [PMID: 33594811 DOI: 10.1111/dth.14883] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]